Obesity, non-alcoholic fatty liver disease, and atherothrombosis: A role for the intestinal microbiota?

Clinical Microbiology and Infection

Volumn 19, Issue 4, 2013, Pages 331-337

  Knaapen, M ^a   Kootte, R S ^a   Zoetendal, E G ^b   de Vos, W M ^b,c   Dallinga Thie, G M ^a   Levi, M ^a   Stroes, E S ^a   Nieuwdorp, M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Atherosclerosis; Atherothrombosis; Intestinal microbiota; Non alcoholic fatty liver disease; Obesity; Thrombosis

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; ENDOTOXIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; PROTHROMBIN; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR; VITAMIN K GROUP;

ACUTE CORONARY SYNDROME; ALGORITHM; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHLAMYDIAL PNEUMONIA; CHOLESTEROL METABOLISM; CHRONIC INFLAMMATION; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTOXEMIA; FECES MICROFLORA; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINE FLORA; INTRAABDOMINAL FAT; KUPFFER CELL; LIPID METABOLISM; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84875508575     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12170     Document Type: Review

References (84)

1. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
2. Nieuwdorp M, Stroes ES, Meijers JC, Buller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005; 5: 155-159.
3. Tunon J, Martin-Ventura JL, Blanco-Colio LM, Lorenzo O, Lopez JA, Egido J. Proteomic strategies in the search of new biomarkers in atherothrombosis. J Am Coll Cardiol 2010; 55: 2009-2016.
4. Henao-Mejia J, Elinav E, Jin C et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012; 482: 179-185.
5. Lassenius MI, Pietilainen KH, Kaartinen K et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34: 1809-1815.
6. Cani PD, Bibiloni R, Knauf C et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
7. Moreno-Navarrete JM, Ortega F, Serino M et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2012; 36: 1442-1449.
8. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.
9. Marchesi JR. Prokaryotic and eukaryotic diversity of the human gut. Adv Appl Microbiol 2010; 72: 43-62.
10. Zoetendal EG, Vaughan EE, De Vos WM. A microbial world within us. Mol Microbiol 2006; 59: 1639-1650.
11. De Vos WM, De Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr Rev 2012; 70 (suppl 1): S45-S56.
12. Booijink CC, Zoetendal EG, Kleerebezem M, De Vos WM. Microbial communities in the human small intestine: coupling diversity to metagenomics. Future Microbiol 2007; 2: 285-295.
13. Backhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723.
14. Nordin AA. The occurrence of plaque forming cells in normal and immunized conventional and germfree mice. Proc Soc Exp Biol Med 1968; 129: 57-62.
15. Komai M, Shirakawa H, Kimura S. Newly developed model for vitamin K deficiency in germfree mice. Int J Vitam Nutr Res 1988; 58: 55-59.
16. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
17. Lagier JC, Armougom F, Million M et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect 2012; 18: 1185-1193.
18. Zoetendal EG, Rajilic-Stojanovic M, De Vos WM. High-throughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57: 1605-1615.
19. Gesta S, Bluher M, Yamamoto Y et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci USA 2006; 103: 6676-6681.
20. Smith JD, Borel AL, Nazare JA et al. Visceral adipose tissue indicates the severity of cardiometabolic risk in patients with and without type 2 diabetes: results from the INSPIRE ME IAA study. J Clin Endocrinol Metab 2012; 97: 1517-1525.
21. Apovian CM, Bigornia S, Mott M et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol 2008; 28: 1654-1659.
22. Wentworth JM, Naselli G, Brown WA et al. Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity. Diabetes 2010; 59: 1648-1656.
23. Sanz Y, Santacruz A, Gauffin P. Gut microbiota in obesity and metabolic disorders. Proc Nutr Soc 2010; 69: 434-441.
24. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.
25. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med 2010; 16: 228-231.
26. Vijay-Kumar M, Gewirtz AT. Role of flagellin in Crohn's disease: emblematic of the progress and enigmas in understanding inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 789-795.
27. Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes 2012; 2012: 879151.
28. Kallio KA, Hyvarinen K, Kovanen PT, Jauhiainen M, Pussinen PJ. Very low density lipoproteins derived from periodontitis patients facilitate macrophage activation via lipopolysaccharide function. Metabolism 2012; doi: 10.1016/j.metabol.2012.09.015. [Epub ahead of print].
29. Birjmohun RS, Van Leuven SI, Levels JH et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol 2007; 27: 1153-1158.
30. Levels JH, Marquart JA, Abraham PR et al. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect Immun 2005; 73: 2321-2326.
31. Harte AL, Varma MC, Tripathi G et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care 2012; 35: 375-382.
32. Nakarai H, Yamashita A, Nagayasu S et al. Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflammation: potential link with metabolic complications. Innate Immun 2012; 18: 164-170.
33. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009; 51: 212-223.
34. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, Hall P et al., eds. Fatty liver disease: NASH and related disorders. Oxford: Blackwell, 2005; 23-37.
35. Bugianesi E, Leone N, Vanni E et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
36. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011; 140: 976-986.
37. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50: 638-644.
38. Dewulf EM, Cani PD, Claus SP et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2012; doi:10.1136/gutjnl-2012-303304.
39. Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010; 28: 737-744.
40. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15: 1546-1558.
41. Kim KA, Gu W, Lee IA, Joh EH, Kim DH. High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS ONE 2012; 7: e47713.
42. Brun P, Castagliuolo I, Di L et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518-G525.
43. Rivera CA, Adegboyega P, van Rooyen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-579.
44. Miyake Y, Yamamoto K. Role of gut microbiota in liver diseases. Hepatol Res 2012; doi: 10.1111/j.1872-034X.2012.01088.x.
45. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-2562.
46. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009; 35: 277-287.
47. Shearer MJ. Vitamin K. Lancet 1995; 345: 229-234.
48. Ramotar K, Conly JM, Chubb H, Louie TJ. Production of menaquinones by intestinal anaerobes. J Infect Dis 1984; 150: 213-218.
49. Conly JM, Stein K. Quantitative and qualitative measurements of K vitamins in human intestinal contents. Am J Gastroenterol 1992; 87: 311-316.
50. Usui Y, Tanimura H, Nishimura N, Kobayashi N, Okanoue T, Ozawa K. Vitamin K concentrations in the plasma and liver of surgical patients. Am J Clin Nutr 1990; 51: 846-852.
51. Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (menaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994; 89: 915-923.
52. Reinhardt C, Bergentall M, Greiner TU et al. Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling. Nature 2012; 483: 627-631.
53. Mortensen FV, Jorgensen B, Christiansen HM, Sloth-Nielsen J, Wolff B, Hessov I. Short-chain fatty acid enemas stimulate plasminogen activator inhibitor-1 after abdominal aortic graft surgery: a double-blinded, placebo-controlled study. Thromb Res 2000; 98: 361-366.
54. Assy N, Bekirov I, Mejritsky Y, Solomon L, Szvalb S, Hussein O. Association between thrombotic risk factors and extent of fibrosis in patients with non-alcoholic fatty liver diseases. World J Gastroenterol 2005; 11: 5834-5839.
55. Kotronen A, Joutsi-Korhonen L, Sevastianova K et al. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int 2011; 31: 176-183.
56. Di Minno MN, Tufano A, Rusolillo A, Di MG, Tarantino G. High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism. World J Gastroenterol 2010; 16: 6119-6122.
57. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
58. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-2753.
59. Stoll LL, Denning GM, Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 2227-2236.
60. Wiedermann CJ, Kiechl S, Dunzendorfer S et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999; 34: 1975-1981.
61. Lehr HA, Sagban TA, Ihling C et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104: 914-920.
62. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010; 31: 817-844.
63. Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90-97.
64. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
65. Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51: 1101-1112.
66. Ikura Y, Ohsawa M, Suekane T et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 2006; 43: 506-514.
67. Speliotes EK, Massaro JM, Hoffmann U et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010; 51: 1979-1987.
68. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497-1502.
69. Salvi P, Ruffini R, Agnoletti D et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010; 28: 1699-1707.
70. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med 1994; 17: 531-539.
71. Shevchuk YM, Conly JM. Antibiotic-associated hypoprothrombinemia: a review of prospective studies, 1966-1988. Rev Infect Dis 1990; 12: 1109-1126.
72. Conly JM, Ramotar K, Chubb H, Bow EJ, Louie TJ. Hypoprothrombinemia in febrile, neutropenic patients with cancer: association with antimicrobial suppression of intestinal microflora. J Infect Dis 1984; 150: 202-212.
73. Figuero E, Sanchez-Beltran M, Cuesta-Frechoso S et al. Detection of periodontal bacteria in atheromatous plaque by nested polymerase chain reaction. J Periodontol 2011; 82: 1469-1477.
74. Koren O, Spor A, Felin J et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA 2011; 108 (suppl 1): 4592-4598.
75. Liu R, Yamamoto M, Moroi M et al. Chlamydia pneumoniae immunoreactivity in coronary artery plaques of patients with acute coronary syndromes and its relation with serology. Am Heart J 2005; 150: 681-688.
76. Grayston JT, Kronmal RA, Jackson LA et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-1645.
77. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
78. Niessner A, Steiner S, Speidl WS et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006; 189: 408-413.
79. Tleyjeh IM, Kashour T, Hakim FA et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009; 169: 1658-1667.
80. Aura AM, Mattila I, Hyotylainen T et al. Drug metabolome of the simvastatin formed by human intestinal microbiota in vitro. Mol BioSyst 2011; 7: 437-446.
81. Sanyal AJ, Chalasani N, Kowdley KV et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685.
82. Tezera LB, Hampton J, Jackson SK, Davenport V. Neisseria lactamica attenuates TLR-1/2-induced cytokine responses in nasopharyngeal epithelial cells using PPAR-gamma. Cell Microbiol 2011; 13: 554-568.
83. Wang D, Xia M, Yan X et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ Res 2012; 111: 967-981.
84. Lahti L, Salonen A, Kekkonen R et al. Associations between the human intestinal microbiota and serum lipids indicated by integrated analysis of high-throughput profiling data. PLoS ONE 2012; e23035.